All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
During the EHA 2022 Congress, the AML Hub spoke with Gert Ossenkoppele, VU University Medical Center, Amsterdam, NL. We asked, Does 10-day decitabine improve post-transplant outcomes in older patients compared with 3+7 chemotherapy?
Does 10-day decitabine improve post-transplant outcomes in older patients compared with 3+7 chemo?
Ossenkoppele begins by introducing the study presented at the congress, outlining the study design and trial results. He then highlights the overall survival, and feasibility of this therapy as a bridge to allogeneic transplant. At the EHA 2022 Congress, Ossenkoppele received the Jean Bernard Lifetime Achievement Award, for his outstanding contribution to the advancement of hematology.
Decitabine shows comparable OS to standard induction chemotherapy and better safety in patients with AML
Lübbert et al. investigated the efficacy and safety of a 10-day decitabine regimen compared to standard IC (“3 + 7”), followed by allografting as...
1st NCRI AML academy meeting | Advances in intensive chemotherapy for patients with AML
We spoke to Prof Gert Ossenkoppele at the 1st NCRI AML academy meeting about recent intensive chemotherapy advances for the treatment of patients with AML (acute...
Subscribe to get the best content related to AML delivered to your inbox